Key result
Enalapril therapy significantly reduced blood pressure and proteinuria in patients with the II/ID ACE genotype, but not in those with the DD genotype.
Why the study?
Does ACE genotype influence the blood pressure-lowering and antiproteinuric effect of enalapril in patients with proteinuric glomerular disease?
Population
36 patients with biopsy-proven proteinuric glomerular diseases, stratified by ACE genotype
Comparison
Enalapril therapy for 6 months vs Comparison between ACE genotype groups
Design
Cohort
Follow-up
6 months
Authors
Loading...
ACE genotyping may inform enalapril response in proteinuric glomerular disease; leaves open prospective validation before practice change.
Cohort (n=36)
Does ACE genotype influence the blood pressure-lowering and antiproteinuric effect of enalapril in patients with proteinuric glomerular disease?
The ACE insertion/deletion polymorphism determines the antiproteinuric and blood pressure-lowering efficacy of enalapril in patients with proteinuric glomerular disease.
Haas et al. (1998) conducted a cohort in Proteinuric glomerular diseases (n=36). Enalapril vs. DD genotype vs ID/II genotype was evaluated on Blood pressure and proteinuria changes. Enalapril therapy significantly reduced blood pressure and proteinuria in patients with the II/ID ACE genotype, but not in those with the DD genotype.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: